| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/100 | Human,Mouse,Rat |
| ICC | 1/100-1/500 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | CD115; CSF-1-R; CSF1R; CSFMR; EC 2.7.10.1 |
| Entrez GeneID | 1436; |
| WB Predicted band size | 130kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Synthesized non-phosphopeptide derived from human CSFR around the phosphorylation site of tyrosine 809 (S-N-Y(p)-I-V). |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是3篇与CSF1R(可能对应Ab-809抗体)相关的参考文献，供参考：
---
1. **标题**: *Targeting tumor-associated macrophages with anti-CSF-1R antibody*
**作者**: Pyonteck SM et al.
**摘要**: 研究验证了一种抗CSF1R抗体(未明确编号)在胶质瘤模型中的作用，证明其通过抑制肿瘤相关巨噬细胞(TAMs)浸润，显著延缓肿瘤进展，为CSF1R靶向治疗提供实验依据。
2. **标题**: *CSF1/CSF1R signaling in myeloid cells: Implications in cancer immunotherapy*
**作者**: Cannarile MA et al.
**摘要**: 综述了CSF1R信号通路在肿瘤微环境中的调控机制，提及多种抗CSF1R抗体的开发(包括部分商业抗体)，强调其在调节巨噬细胞极化和增强免疫检查点疗法中的作用。
3. **标题**: *Preclinical characterization of a novel anti-CSF1R monoclonal antibody for solid tumors*
**作者**: Xu J et al.
**摘要**: 报道了一种新型抗CSF1R单抗(可能为Ab-809同类)的临床前研究，证实其阻断配体结合并抑制下游信号，在乳腺癌和结肠癌模型中减少TAMs并增强化疗效果。
---
**说明**：
- 因“Ab-809”可能为特定厂商编号(如Abcam产品ab809)，建议直接参考抗体供应商提供的文献引用(如产品手册引用的研究)。
- 上述文献为CSF1R抗体功能相关示例，实际研究中需结合具体抗体编号和实验背景筛选文献。
The CSFR (Colony Stimulating Factor 1 Receptor), also known as CSF1R or CD115. is a tyrosine kinase receptor critical for regulating the survival, differentiation, and function of macrophages and monocytes. Dysregulation of CSF1R signaling is implicated in diseases like cancer, inflammatory disorders, and neurodegenerative conditions. In oncology, tumor-associated macrophages (TAMs), driven by CSF1R activation, often promote immunosuppression, angiogenesis, and metastasis, making CSF1R a therapeutic target.
Ab-809 is a monoclonal antibody designed to specifically target CSF1R. By binding to the receptor, it blocks the interaction between CSF1R and its ligands (CSF-1 and IL-34), thereby inhibiting downstream signaling pathways like MAPK and PI3K/AKT. This suppression reduces TAM proliferation and reprograms the tumor microenvironment to enhance anti-tumor immunity. Preclinical studies suggest Ab-809 may synergize with checkpoint inhibitors or chemotherapy by overcoming immune evasion.
Beyond cancer, CSF1R inhibitors like Ab-809 are explored in inflammatory diseases (e.g., rheumatoid arthritis) where macrophage overactivation drives tissue damage. While early-phase trials highlight potential, challenges remain in managing on-target toxicities, such as liver enzyme elevations or skin reactions. Ongoing research aims to optimize dosing and identify biomarkers to stratify patients likely to benefit from CSF1R-targeted therapies.
×
